公开(公告)号：US12233059B2

公开(公告)日：2025-02-25

申请号：US18670637

申请日：2024-05-21

Applicant: Alto Neuroscience, Inc.

Inventor： Amit Etkin ,  Wei Wu ,  Chao Wang ,  Nicholas Cooper ,  Joshua Jordan ,  Adam Savitz

IPC: A61K31/496 ,  A61K9/00 ,  A61K31/19 ,  A61K31/53 ,  A61K33/00 ,  A61P25/24 ,  A61B5/16 ,  A61B5/374

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

公开(公告)号：US12208096B2

公开(公告)日：2025-01-28

申请号：US18670627

申请日：2024-05-21

Applicant: Alto Neuroscience, Inc.

Inventor： Amit Etkin ,  Wei Wu ,  Chao Wang ,  Nicholas Cooper ,  Joshua Jordan ,  Adam Savitz

IPC: A61K31/496 ,  A61B5/16

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MIDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.